Myelodysplastic Syndrome (MDS) with del(5q) represents a unique WHO entity, which is
often treated with lenalidomide according to standard clinical practice. Guidelines
concerning treatment duration have thus far not been implemented, but rather
comprise an indefinite therapy until loss of response. This review presents three red
blood cell (RBC) transfusion-dependent MDS with del(5q) cases, starting with one rare
case with an unbalanced translocation t(2;5), involving the breakpoint of del(5q) and loss
of the 5q15-5q31 region. To the best of our knowledge, no comparable case has been
described before with a response to lenalidomide. Strikingly, treatment-induced and
maintained cytogenetic complete remission (cCR) in this patient. Furthermore, we report
two cases of classical del(5q), in which lenalidomide was interrupted after a short period of
lenalidomide therapy at the time cCR was achieved. Despite drug holiday cCR was
maintained for seven and nine years, respectively. Then del(5q) re-emerged in the
absence of novel molecular aberrations and re-treatment with lenalidomide could again
achieve cCR in both cases. Together, this series presents three cases of personalized
therapy of MDS with del(5q)
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:85861 |
| Date | 08 June 2023 |
| Creators | Stein, Anna, Kubasch, Anne Sophie, Haferlach, Claudia, Platzbecker, Uwe |
| Publisher | Frontiers Media S.A. |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 866470 |
Page generated in 0.0021 seconds